New Data for DARZALEX ® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Myeloma | Pharmaceuticals